Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Evidation, founded in 2012 and headquartered in San Mateo, California, is a leading player in the digital health measurement and engagement sector. The company specializes in harnessing real-world health data to improve health outcomes, serving life sciences companies, government bodies, and academic institutions. Evidation's platform utilizes data science and machine learning to provide health guidance, treatments, and tools.
Since its inception, Evidation has demonstrated significant growth and attracted substantial investor interest. The company has successfully raised $259.18 million across multiple funding rounds, with its latest Series E round in March 2021 securing $153 million. This funding round valued Evidation at $1 billion, marking its entry into the unicorn club of privately held companies valued at over $1 billion.
Evidation's impressive funding history and valuation growth have naturally led to speculation about a potential initial public offering (IPO). However, as of now, there are no confirmed reports or official announcements regarding Evidation's IPO plans. The company's future steps towards going public remain uncertain.
Several factors could influence Evidation's decision to pursue an IPO, including market conditions, the company's financial performance, and its strategic goals. The competitive landscape in the digital health sector, featuring companies like Medable and Tempus, may also play a role in Evidation's considerations. However, without official information from the company, any discussion of IPO timing or likelihood remains speculative.
Investors interested in Evidation should keep an eye on official company announcements and industry news for any updates on potential IPO plans. As always, it's crucial to conduct thorough research and consider various factors before making investment decisions.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Evidation's IPO prospects remain uncertain, investors eager to gain exposure to innovative health tech companies don't have to wait. At Linqto, we offer members access to interests in pre-IPO private companies, including potential leaders in the digital health and data analytics sectors. Our platform allows you to diversify your portfolio with lower minimum investments in promising companies like Evidation, potentially benefiting from their growth before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
